- Home
- SURG vs ACRV Comparison
SURG vs ACRV Comparison
Compare SURG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- ACRV
- Stock Information
- Founded
- SURG 2006
- ACRV 2018
- Country
- SURG United States
- ACRV United States
- Employees
- SURG N/A
- ACRV N/A
- Industry
- SURG Advertising
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- SURG Consumer Discretionary
- ACRV Health Care
- Exchange
- SURG Nasdaq
- ACRV Nasdaq
- Market Cap
- SURG 58.6M
- ACRV 47.8M
- IPO Year
- SURG N/A
- ACRV 2022
- Fundamental
- Price
- SURG $2.82
- ACRV $1.89
- Analyst Decision
- SURG Strong Buy
- ACRV Buy
- Analyst Count
- SURG 1
- ACRV 6
- Target Price
- SURG $9.50
- ACRV $17.75
- AVG Volume (30 Days)
- SURG 90.0K
- ACRV 577.9K
- Earning Date
- SURG 11-11-2025
- ACRV 11-12-2025
- Dividend Yield
- SURG N/A
- ACRV N/A
- EPS Growth
- SURG N/A
- ACRV N/A
- EPS
- SURG N/A
- ACRV N/A
- Revenue
- SURG $36,461,935.00
- ACRV N/A
- Revenue This Year
- SURG $47.01
- ACRV N/A
- Revenue Next Year
- SURG $81.15
- ACRV $805.34
- P/E Ratio
- SURG N/A
- ACRV N/A
- Revenue Growth
- SURG N/A
- ACRV N/A
- 52 Week Low
- SURG $1.05
- ACRV $1.05
- 52 Week High
- SURG $3.47
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- SURG 50.29
- ACRV 69.76
- Support Level
- SURG $2.51
- ACRV $1.77
- Resistance Level
- SURG $2.90
- ACRV $1.99
- Average True Range (ATR)
- SURG 0.14
- ACRV 0.12
- MACD
- SURG -0.01
- ACRV 0.02
- Stochastic Oscillator
- SURG 56.00
- ACRV 84.11
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.